77
Participants
Start Date
December 21, 2021
Primary Completion Date
October 31, 2024
Study Completion Date
January 14, 2025
Enzalutamide
Daily oral dose of enzalutamide
EPI-7386 with Enzalutamide
Daily oral dose of EPI-7386 in combination of enzalutamide
St. Vincent's Hospital Sydney, Darlinghurst
Chris O'Brien Lifehouse, Camperdown
The Canberra Hospital, Garran
Eastern Health, Box Hill
Memorial Sloan Kettering Cancer Center, New York
Great Lakes Cancer Center, Buffalo
Roswell Park Comprehensive Cancer Center, Buffalo
Chesapeake Urology Associates, Baltimore
Johns Hopkins University, Baltimore
Carolina Urologic Research Center, Myrtle Beach
Moffitt Cancer Center, Tampa
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
University of Wisconsin, Madison
Washington University Siteman Cancer Center, St Louis
Urology Cancer Center, Omaha
Arizona Urology, Tucson
OHSU Knight Cancer Instititue, Portland
Tom Baker Cancer Centre, Calgary
Prostate Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Hamilton
Princess Margaret Cancer Center, Toronto
Centre Hospitalier de l'Universite de Montreal, Montreal
Jewish General Hospital, Montreal
Lead Sponsor
ESSA Pharmaceuticals
INDUSTRY